Pune, India, September 2018/MRFR Press Release/- Market Research Future published a half-cooked research report on the Global ADME Toxicology Testing Market.
The Global ADME Toxicology Testing Market is expected to witness tremendous growth owing to as increasing number of drug developments coupled with increasing demand from various pharmaceutical and biotechnology companies worldwide due to reduction in the costs involved in various tests during the drug development process. Other key factors such reduced new drug commercialization time and reduction in the number of drug failures that occurred earlier mainly due to ADME and Toxicology issues are contributing towards the growth of the market. However, factors such as lack of technological advancements is likely to curb the market growth during the forecast period.
The Global ADME Toxicology Testing Market is segmented on the basis of method, technology, application, and end-user. The ADME toxicology testing market, by method is categorized into cellular assay, biochemical assay, in silica, and ex-vivo. The technology segment is categorized into cell culture, high throughput, molecular imaging, and OMICS technology. On the basis of application, the ADME toxicology testing market is segmented into systemic toxicity, renal toxicity, hepatotoxicity, neurotoxicity, and others. On the basis of end-user, the market is segmented into hospitals and clinics, diagnostic centers, pathological labs, and others.
The Americas is the largest in the market owing to the high acceptance of ADME toxicology testing in research. Moreover, the development in research expenditure are also accountable for the growth of the ADME toxicology testing market. For instance, in October 2014, the Wuxi Pharma Tech acquired Xenobiotic Laboratories, Inc. to assist its ADME, drug metabolism and pharmacokinetic (DMPK) and bioanalytical services. The company plans to expand its integrated service portfolio for laboratory testing division in North America.
The European region is the second largest ADME toxicology testing market during the forecast period. The increased focus of leading biopharmaceutical manufacturer to expand their subsidiaries in these countries. Consequently, the growing number of pathological facilitate the market growth of this diagnostic type.
The Asia Pacific region is likely to develop at the uppermost CAGR for the ADME toxicology testing market in the years to come. Moreover, the rising oncology and palliative care services both at the hospital level and in the community are expected to influence the market in a positive way.
The Middle East and Africa accounts for the least share due to low per capita income and lack of availability of well-trained healthcare professionals. However, there has been an increasing demand for test accuracy and consistency among end-users and the government in this region that is enhancing the adoption of hyperspectral imaging technology in this region.
Browse Complete Report @ https://www.marketresearchfuture.com/reports/adme-toxicology-testing-market-6945
Some of the key players in the global ADME toxicology testing market are Promega Corporation, Agilent Technologies, Inc., Thermo Fisher Scientific, Inc., Bio-Rad Laboratories, Inc., Beckman Coulter, Inc., Cellartis AB, Cyprotex PLC., Life Technologies Corporation, Optivia Biotechnology, Inc., Accelrys, Inc., Molecular Discovery Ltd., Cyprotex PLC, MultiCASE, Inc., Caliper Life Sciences, Inc., Xceleron, Inc., ACEA Biosciences, Inc., Albany Molecular Research, Inc., CeeTox, Inc., and others.
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
+1 646 845 9312
Email: email@example.com .